Company Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Biotechnology & Medical Research

Business description: Guard Therapeutics International AB

Sales by Activity: Guard Therapeutics International AB

Geographical breakdown of sales: Guard Therapeutics International AB

Managers: Guard Therapeutics International AB

Members of the board: Guard Therapeutics International AB

Shareholders: Guard Therapeutics International AB

Company details: Guard Therapeutics International AB

Other Biotechnology & Medical Research

Sector

Annual profits - Rate of surprise

Income Statement and Estimates

Delayed Nasdaq Stockholm Other stock markets 16:17:35 13/09/2024 BST			5-day change	1st Jan Change
28.20 ^SEK	-2.76%		-2.08%	-21.23%

08-29	First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	CI
08-27	Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	MT

A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Number of employees: 11

Fiscal Period: December	2019	2020	2021	2022	2023

See all business segments

Fiscal Period: December	2019	2020	2021	2022	2023

See all geographic segments

Director	Title	Age	Since
Tobias Larsson Agervald CEO	Chief Executive Officer	48	30/11/18
Karin Botha DFI	Director of Finance/CFO	51	13/09/20
Michael Reusch CTO	Chief Tech/Sci/R&D Officer	64	31/12/21
Sara Thuresson CTO	Chief Tech/Sci/R&D Officer	48	23/05/21
Torbjörn Larsson PRN	Corporate Officer/Principal	-	30/04/22

See GUARD THERAPEUTICS INTERNATIONAL AB governance

Manager	Title	Age	Since
Göran Forsberg BRD	Director/Board Member	61	28/05/19
Johannes Hulthe BRD	Director/Board Member	54	28/05/19
Johan Bygge CHM	Chairman	68	30/04/21
Fredrik Lehmann BRD	Director/Board Member	48	30/11/22
Khatereh Ahmadi BRD	Director/Board Member	-	04-30
Hege Hellstrom BRD	Director/Board Member	59	04-30

Composition of the Board of Directors

Name	Equities	%	Valuation
Strand Kapitalförvaltning AB 3.506 %	422,690	3.506 %	1 M kr
FCG Fonder AB 0.0144 %	1,732	0.0144 %	4 939 kr

List of GUARD THERAPEUTICS INTERNATIONAL AB shareholders

Guard Therapeutics International AB

Nybrogatan 34 2nd Floor

114 39, Stockholm

+46 86 70 65 51

http://www.guardtherapeutics.com

address Guard Therapeutics International AB(GUARD)

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GUARD THERAPEUTICS INTERNATIONAL AB	-2.76%	-2.08%	+259.24%	-68.63%	33.88M
LONZA GROUP AG	+2.01%	+3.28%	+14.02%	-27.30%	45.91B
IQVIA HOLDINGS INC.	-0.20%	-1.97%	+10.01%	-6.77%	43.46B
ALNYLAM PHARMACEUTICALS, INC.	+0.62%	+6.74%	+36.44%	+41.78%	33.6B
CELLTRION, INC.	+2.57%	+4.04%	+33.79%	-22.43%	30.11B
MODERNA, INC.	-4.84%	-9.51%	-39.26%	-84.29%	26.78B
ICON PUBLIC LIMITED COMPANY	+0.63%	-0.46%	+13.59%	+17.28%	24.82B
UNITED THERAPEUTICS CORPORATION	-0.01%	-1.40%	+53.27%	+62.58%	15.18B
BIO-TECHNE CORPORATION	+1.18%	+3.52%	+2.10%	-41.10%	11.61B
MEDPACE HOLDINGS, INC.	+0.90%	+3.92%	+23.87%	+87.96%	10.67B
Average	+0.01%	-0.36%	+40.71%	-4.09%	24.22B
Weighted average by Cap.	+0.38%	-0.51%	+15.29%	-5.12%

See all sector performances

Profit revisions

Estimate revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

More financial data